ADC Therapeutics SA Quarterly Operating Income (Loss) in USD from Q1 2023 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
ADC Therapeutics SA quarterly/annual Operating Income (Loss) history and growth rate from Q1 2023 to Q2 2024.
  • ADC Therapeutics SA Operating Income (Loss) for the quarter ending June 30, 2024 was -$29M, a 26.8% increase year-over-year.
  • ADC Therapeutics SA annual Operating Income (Loss) for 2023 was -$166M, a 34.6% decline from 2022.
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$29M +$10.6M +26.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 -$33.6M +$16.6M +33.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-06
Q2 2023 -$39.6M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$50.2M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.